医学
多塔
骨转移
前列腺癌
耐火材料(行星科学)
转移
骨痛
骨显像
肿瘤科
核医学
癌症
内科学
体内
物理
生物技术
天体生物学
生物
作者
Hongmei Li,Tingting Xu,Qingchu Hua,Li Wang,Yue Chen
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2023-05-26
卷期号:48 (8): 740-742
被引量:1
标识
DOI:10.1097/rlu.0000000000004717
摘要
Bone is the most common metastatic site in patients with prostate cancer. 177Lu-DOTA-ibandronic acid (177Lu-DOTA-IBA) is a new therapeutic radiopharmaceutical targeting bone metastasis. We report a case of refractory bone pain due to bone metastasis, who demonstrated an excellent therapy response after 3 cycles of 177Lu-DOTA-IBA therapy. In addition, the patient did not have any observable adverse reactions. 177Lu-DOTA-IBA may be a promising radiopharmaceutical for the treatment of bone metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI